Fig. 2From: Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primatesRepresentative time activity curves of [11C]PF-06809247 in the NHP brain at a baseline and b following pretreatment with a selective MAGL inhibitor (NHP4; 0.42 mg/kg). cer cerebellum, cau caudate, put putamen, tha thalamus, fro frontal cortex, tem temporal cortex, hip hippocampusBack to article page